Advancing Collaborative Implementation of Personalised Medicine Approaches in Healthcare
Call Announcement & Projects
The call documents of the EP PerMed Twinning Call 2026 were published in December 2025. The call is closed, but if you are interested in the original documents, you can read them here. The 6 funded projects can be found in the EP PerMed Project Database.
Announcement of Results
Six high-quality projects have been selected for funding under the EP PerMed Twinning Call 2026, an initiative designed to accelerate the implementation of personalised medicine approaches across Europe through the transfer of knowledge, expertise, and proven practices between healthcare organisations.
Personalised medicine marks a significant shift away from the traditional “one size fits all” approach. As defined in the European Council Conclusion on personalised medicine for patients (2015/C 421/03), it refers to a medical model that uses the characterisation of individuals’ phenotypes and genotypes, such as molecular profiling, medical imaging, and lifestyle data, to tailor the right therapeutic strategy to the right person at the right time, and/or to determine disease predisposition and deliver timely, targeted prevention. This approach has the potential to transform healthcare systems and significantly improve patient outcomes.
Launched in December 2025, the Twinning Call provided up to €50,000 per project to support the transfer and implementation of mature personalised medicine solutions and approaches between organisations in different Horizon Europe countries. Through structured Twinning partnerships, organisations share knowledge, concepts, skills, and implementation experience to strengthen local capacities and facilitate the adoption of innovative personalised medicine approaches within healthcare systems.
The call attracted 20 applications from organisations across Europe specialising in personalised medicine implementation, healthcare delivery, and innovation. Following a rigorous eligibility check, independent expert evaluation, and online pitching process, six projects were selected for funding, representing a total investment of approximately €300,000.
Each selected project focuses on the implementation and transfer of a personalised medicine solution or approach within one of the following healthcare areas:
- Neurological
- Cardiovascular
- Mental Health
- Generic Health Relevance
These projects support the adoption of innovative personalised medicine approaches in healthcare settings across Europe through capacity building, knowledge transfer, and cross-border collaboration. By facilitating the transfer of proven solutions and implementation expertise between organisations, the projects aim to strengthen healthcare system capabilities and improve patient outcomes through the wider adoption of personalised medicine.
The implementation phase of the selected projects will run over a 12‑month period, during which participating organisations will engage in knowledge exchange activities, training, site visits, and implementation planning to embed personalised medicine approaches within their local healthcare settings.
We are pleased to present these selected projects, which demonstrate the value of international collaboration, knowledge transfer, and capacity building in accelerating the implementation of personalised medicine across Europe and bringing innovative, patient-centred healthcare solutions closer to routine clinical practice.
Funded Projects
Personalised Connectivity-Guided Decision-Making in Pediatric Epilepsy Surgery – A European Twinning Action (CONNECT-Epi)
Healthcare Category: Neurological
Consortium:
- Meyer Children’s Hospital IRCCS (Twinning Receiver / Project Lead)
- King’s College London (Twinning Donor)
The CONNECT-Epi project aims to implement personalised medicine in paediatric epilepsy surgery by transferring advanced diffusion MRI tractography expertise from King’s College London to Meyer Children’s Hospital. The project will support the integration of patient-specific brain connectivity mapping into routine surgical planning and intraoperative guidance, enabling treatment decisions tailored to each child’s unique neuroanatomy. Through training, protocol harmonisation, and the establishment of standardised workflows, the partnership seeks to improve surgical precision, increase seizure-free outcomes, and reduce postoperative neurological deficits. The project aims to create a sustainable and scalable model for personalised neurosurgical care that can be adopted by other centres across Europe.
Personalised Access Transfer for Healthcare Within Across-border sYstems – Implementation of a Personalised Neurorehabilitation Pathway (PATHWAY)
Healthcare Category: Neurological
Consortium:
- San Camillo IRCCS Neurorehabilitation Research Hospital (Twinning Donor / Project Lead)
- University of Rzeszów (Twinning Receiver)
The PATHWAY project aims to transfer and implement a mature personalised neurorehabilitation pathway from Italy to Poland. Focusing on organisational and clinical integration, the project will enable the routine delivery of personalised, data-driven rehabilitation through patient stratification approaches, scalable supervision models, and the integration of validated digital tools into clinical workflows. Through training, knowledge exchange, and adaptation of standardised procedures, the partnership seeks to improve access to high-quality personalised rehabilitation, increase healthcare efficiency, and provide a scalable model for wider implementation of personalised medicine across Europe.
Strengthening Cardiovascular Pharmacogenomics Implementation through Twinning (CardioPgX-TWIN)
Healthcare Category: Cardiovascular
Consortium:
- Lithuanian University of Health Sciences (Twinning Receiver / Project Lead)
- University of Extremadura (Twinning Donor)
The CardioPgX-TWIN project aims to enable the routine use of pharmacogenomics in cardiovascular medicine by transferring a clinically proven personalised prescribing system from Spain to Lithuania. The project focuses on integrating genetic information into everyday cardiovascular treatment decisions through clinical workflows, governance frameworks, and decision-support tools tailored to individual patient profiles. Through capacity building, multidisciplinary collaboration, and the development of implementation roadmaps, the project seeks to improve treatment effectiveness, reduce adverse drug reactions, and support more precise and evidence-based prescribing practices.
Accelerating the implementation and adoption of the first-in-class aid-to-diagnosis blood test in precision psychiatry, myEDIT-B, from France to Spain (IMPL-EDIT)
Healthcare Category: Mental Health
Consortium:
- Alcediag (Twinning Donor / Project Lead)
- Ita Salud Mental (Twinning Receiver)
The IMPL-EDIT project aims to implement a validated personalised medicine approach in psychiatry by transferring the myEDIT-B blood test from France to Spain and integrating it into routine clinical practice. The project supports psychiatrists in distinguishing between depression and bipolar disorder through the use of biological biomarkers alongside clinical assessment, thereby reducing diagnostic uncertainty and delays. Through training, pilot implementation, and real-world evaluation, the partnership will build institutional capacity and demonstrate the feasibility of scaling precision psychiatry solutions across healthcare systems, ultimately supporting earlier and more personalised treatment decisions.
Pharmacogenetics based on NGS/WGS (NGS/WGS-PGx)
Healthcare Category: Generic Health Relevance
Consortium:
- University of Zurich (Twinning Donor / Project Lead)
- University of Heidelberg (Twinning Receiver)
The NGS/WGS-PGx project aims to expand the implementation of personalised medicine by transferring a clinically validated pharmacogenomics service from Switzerland to Germany. The partnership will facilitate the integration of next-generation sequencing (NGS) and whole-genome sequencing (WGS) pharmacogenetic data into routine clinical decision-making. Activities include staff training, workshops, genomic data interpretation, and the harmonisation of testing and consultation workflows. By enabling genetics-guided prescribing, the project seeks to improve treatment safety and efficacy, reduce adverse drug reactions, and create a scalable model for broader implementation of pharmacogenomics across European healthcare systems.
BRIdging knowleDGE for the implementation of Pyridoxine-Dependent Epilepsy in Newborn Screening Programs (BRIDGE-PDE)
Healthcare Category: Neurological
Consortium:
- Meyer Children’s Hospital IRCCS (Twinning Donor / Project Lead)
- National Institute of Health Dr. Ricardo Jorge
- Hospital Clínic de Barcelona | Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
The BRIDGE-PDE project aims to transfer and implement a validated newborn screening method for pyridoxine-dependent epilepsy (PDE), enabling earlier diagnosis of this rare genetic disorder before symptoms appear. Through training, knowledge transfer, and the adoption of harmonised protocols, the project seeks to integrate a biomarker-based personalised medicine approach into routine public health screening. The partnership aims to improve patient outcomes, reduce healthcare inequalities, support future policy decisions on newborn screening programmes, and establish a sustainable implementation model that can be extended to other rare diseases and healthcare settings.